ليتروزول تيڤع

Land: Israel

Sprache: Arabisch

Quelle: Ministry of Health

Wirkstoff:

LETROZOLE 2.5 MG

Verfügbar ab:

TEVA PHARMACEUTICAL INDUST.LTD

ATC-Code:

L02BG04

Darreichungsform:

TABLETS

Verabreichungsweg:

PER OS

Hergestellt von:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Therapiegruppe:

LETROZOLE

Anwendungsgebiete:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Berechtigungsdatum:

2010-01-01